Castle Biosciences, Inc. (NASDAQ:CSTL) Shares Purchased by Knights of Columbus Asset Advisors LLC

Knights of Columbus Asset Advisors LLC raised its holdings in shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 99.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 106,262 shares of the company's stock after purchasing an additional 52,921 shares during the period. Knights of Columbus Asset Advisors LLC owned approximately 0.39% of Castle Biosciences worth $2,293,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. BluePath Capital Management LLC purchased a new stake in Castle Biosciences during the 3rd quarter valued at $31,000. Royal Bank of Canada boosted its stake in Castle Biosciences by 40.5% during the 2nd quarter. Royal Bank of Canada now owns 2,880 shares of the company's stock valued at $39,000 after purchasing an additional 830 shares during the last quarter. Tower Research Capital LLC TRC boosted its stake in Castle Biosciences by 61.2% during the 3rd quarter. Tower Research Capital LLC TRC now owns 1,821 shares of the company's stock valued at $47,000 after purchasing an additional 691 shares during the last quarter. Osaic Holdings Inc. boosted its stake in Castle Biosciences by 37.2% during the 2nd quarter. Osaic Holdings Inc. now owns 3,626 shares of the company's stock valued at $50,000 after purchasing an additional 984 shares during the last quarter. Finally, Lazard Asset Management LLC bought a new position in shares of Castle Biosciences during the 1st quarter valued at $57,000. 92.60% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, insider Derek J. Maetzold sold 2,295 shares of the firm's stock in a transaction on Wednesday, March 20th. The stock was sold at an average price of $20.27, for a total value of $46,519.65. Following the transaction, the insider now directly owns 69,806 shares of the company's stock, valued at approximately $1,414,967.62. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, Director Daniel Bradbury sold 2,074 shares of the business's stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $23.20, for a total value of $48,116.80. Following the transaction, the director now directly owns 33,870 shares in the company, valued at $785,784. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Derek J. Maetzold sold 2,295 shares of the business's stock in a transaction dated Wednesday, March 20th. The shares were sold at an average price of $20.27, for a total value of $46,519.65. Following the completion of the transaction, the insider now owns 69,806 shares in the company, valued at $1,414,967.62. The disclosure for this sale can be found here. In the last three months, insiders have sold 50,062 shares of company stock valued at $1,051,065. 7.70% of the stock is owned by company insiders.

Analyst Ratings Changes

CSTL has been the topic of several research analyst reports. Scotiabank increased their price target on Castle Biosciences from $33.00 to $37.00 and gave the company a "sector outperform" rating in a report on Friday, March 1st. KeyCorp increased their price target on Castle Biosciences from $25.00 to $28.00 and gave the company an "overweight" rating in a report on Friday, March 1st.

Castle Biosciences Trading Up 0.6 %

Castle Biosciences stock traded up $0.11 during trading on Friday, reaching $19.31. The company had a trading volume of 129,601 shares, compared to its average volume of 153,253. Castle Biosciences, Inc. has a 52 week low of $9.26 and a 52 week high of $26.70. The firm's 50-day simple moving average is $21.53 and its 200 day simple moving average is $19.90. The firm has a market capitalization of $530.06 million, a price-to-earnings ratio of -8.94 and a beta of 0.93.

Castle Biosciences (NASDAQ:CSTL - Get Free Report) last announced its earnings results on Wednesday, February 28th. The company reported ($0.10) EPS for the quarter, topping analysts' consensus estimates of ($0.84) by $0.74. Castle Biosciences had a negative return on equity of 14.92% and a negative net margin of 26.15%. The company had revenue of $66.12 million for the quarter, compared to analysts' expectations of $51.32 million. On average, analysts predict that Castle Biosciences, Inc. will post -2.41 earnings per share for the current year.

Castle Biosciences Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.